Friday, July 4, 2025
|
12:00 - 12:30
| Sponsored by MSD: Real-world Immunotherapy Strategies for the Management of Resectable NSCLC
| Dr. Taher Abu Hejleh
|
12:30 - 13:00
| Sponsored by AstraZeneca: Reach Beyond with the Perioperative AEGEAN Regimen
| Dr. Fady Farhat
|
15:20 - 17:50
| Sponsored by Roche: The Goal is Cure: Role of Tecentriq in Early Non-Small Cell Lung Cancer
| Dr. Layal El Halabi
|
18:00 - 18:30
| Sponsored by Johnson & Johnson: Amivantamab in NSCLC with Common EGFRm Patients: A New Treatment Paradigm
| Dr. Arafat Tfayli
|
|
| Saturday, July 5, 2025 |
08:40 - 09:00
| Sponsored by Johnson & Johnson: Amivantamab in NSCLC with EGFR exon 20 Insertion: The New Standard of Care
| Dr. Nizar Bitar
|
10:40 - 11:10
| Sponsored by BMS: The Emerging Role of Immunotherapy in Resectable NSCLC
| Dr. Ahmad Younis
|